Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT01734928 · COMPLETED

Trial details

NCT number: NCT01734928
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2013-01-07
Primary completion: 2022-05-09
Enrollment: 559

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.